Evidence map›Paper›PMID 24938649›Full record

ArticleLeukemia2015

Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

P Satwani, Z Jin, P L Martin, M Bhatia, J H Garvin, D George, S Chaudhury, J Talano, E Morris, L Harrison and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies.Blood and lymphatic cancer : targets and therapy · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

P SatwaniDepartment of Pediatrics, Columbia University, New York, NY, USA.
Z JinDepartment of Biostatistics, Columbia University, New York, NY, USA.
P L MartinDepartment of Pediatrics, Duke University, Durham, NC, USA.
M BhatiaDepartment of Pediatrics, Columbia University, New York, NY, USA.
J H GarvinDepartment of Pediatrics, Columbia University, New York, NY, USA.
D GeorgeDepartment of Pediatrics, Columbia University, New York, NY, USA.
S ChaudhuryDepartment of Pediatrics, Northwestern University, Chicago IL, USA.
J TalanoDepartment of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
E MorrisDepatment of Pediatrics, New York Medical College, Valhalla, NY, USA.
L HarrisonDepatment of Pediatrics, New York Medical College, Valhalla, NY, USA.
J SosnaDepartment of Pediatrics, Columbia University, New York, NY, USA.
M PetersonDepartment of Pediatrics, Duke University, Durham, NC, USA.
O MilitanoDepatment of Pediatrics, New York Medical College, Valhalla, NY, USA.
S FoleyDepatment of Pediatrics, New York Medical College, Valhalla, NY, USA.
J KurtzbergDepartment of Pediatrics, Duke University, Durham, NC, USA.
M S Cairo1] Depatment of Pediatrics, New York Medical College, Valhalla, NY, USA [2] Departments of Medicine, Pathology, Microbiology and Anatomy, New York Medical College, Valhalla, NY, USA.
Columbia University · USNew York Medical College · USDuke University · USMedical College of Wisconsin · USNorthwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden. We conducted a multi-center prospective study of myeloablative conditioning (MAC) and autologous stem cell transplantation (AutoSCT), followed by a reduced intensity conditioning (RIC) and allogeneic hematopoietic cell transplantation (AlloHCT) in CAYA, with poor-risk refractory or recurrent lymphoma. Conditioning for MAC AutoSCT consisted of carmustine/etoposide/cyclophosphamide, RIC consisted of busulfan/fludarabine. Thirty patients, 16 Hodgkin lymphoma (HL) and 14 non-Hodgkin lymphoma (NHL), with a median age of 16 years and median follow-up of 5years, were enrolled. Twenty-three patients completed both MAC AutoSCT and RIC AlloHCT. Allogeneic donor sources included unrelated cord blood (n=9), unrelated donor (n=8) and matched siblings (n=6). The incidence of transplant-related mortality following RIC AlloHCT was only 12%. In patients with HL and NHL, 10 year EFS was 59.8% and 70% (P=0.613), respectively. In summary, this approach is safe, and long-term EFS with this approach is encouraging considering the poor-risk patient characteristics and the use of unrelated donors for RIC AlloHCT in the majority of cases.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultChildChild, PreschoolDisease ProgressionFetal BloodGraft vs Tumor EffectHLA AntigensHodgkin DiseaseHumansLymphoma, Non-HodgkinPrognosisProspective StudiesRecurrenceTransplantation, AutologousHLA Antigens

Identifiers

PMID24938649
OpenAlexW2008143837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.